

---

# Integrative Network Analysis: Unveiling Symptom-Disease Interactions and Enhancing Predictive Models

---

Andreoli C. • Ligari D. • Alberti A. • Scardovi M.<sup>1</sup>

<sup>1</sup> *Department of Computer Engineering, Data Science, University of Pavia, Italy  
Course of Financial Data Science*

Github page: <https://github.com/DavideLigari01/financial-project>

Date: December 18, 2023

---

**Abstract** — This study addresses the complex challenge of deciphering the relationships between symptoms and diseases in healthcare, a crucial aspect for accurate diagnosis and predictive analytics. Employing network analysis, we blend theoretical and empirical approaches to understand these relationships. Our work primarily focuses on exploring complex network configurations, utilizing bipartite models and non-weighted edges to identify significant patterns in disease-symptom interactions. A key aspect of our research is the application of novel metrics, inspired by Hidalgo's works from 2007 and 2009, to classify symptoms and diseases based on their predictive power. These innovative metrics, along with traditional ones like betweenness centrality, are instrumental in refining our predictive models.

Building upon this foundation, we delve into predictive modeling, aspiring to surpass existing benchmarks in the field. Our approach centers on three proven machine learning models—Logistic Regression, Random Forest, and Multi-Layer Perceptron—each chosen for their demonstrated effectiveness in disease prediction using symptomatic data, as evidenced in the studies by Kohli, Singh, and Uddin (2019). Through this study, we aim to advance the understanding and capabilities in disease prediction, providing valuable insights for the healthcare sector.

**Keywords** —Graph theory • Features Engineering • Community detection • Null models • Random forest • MLP

---

|                 |  |          |  |                                    |           |
|-----------------|--|----------|--|------------------------------------|-----------|
| <b>CONTENTS</b> |  | d        | Operative Flow . . . . .   | 10                                 |           |
| <b>1</b>        | <b>Introduction</b>                    | <b>1</b> | <b>7</b>   | <b>ML Model Results</b>            | <b>12</b> |
| <b>2</b>        | <b>Dataset</b>                         | <b>2</b> | a  | Model Selection . . . . .          | 12        |
| <b>3</b>        | <b>Goals</b>                           | <b>2</b> | b  | New Features Effect . . . . .      | 13        |
| <b>4</b>        | <b>Network Methodology</b>             | <b>2</b> | c  | Best Model Analysis . . . . .      | 13        |
| a               | Network Creation . . . . .             | 2        | d  | Computational Complexity . . . . . | 16        |
| b               | Method of Reflections . . . . .        | 3        | <b>8</b>   | <b>Conclusion</b>                  | <b>18</b> |
| c               | Betweenness Centrality . . . . .       | 4        | <b>9</b>   | <b>Limits and Future Works</b>     | <b>18</b> |
| d               | Communities Detection . . . . .        | 4        | a  | Limits . . . . .                   | 18        |
| <b>5</b>        | <b>Network Results</b>                 | <b>4</b> | b  | Future Work . . . . .              | 18        |
| a               | Method of reflection . . . . .         | 4        | <b>10</b>  | <b>Appendix</b>                    | <b>19</b> |
| b               | Betweenness Centrality . . . . .       | 6        | <b>1. INTRODUCTION</b>   |                                    |           |
| c               | Communities . . . . .                  | 7        | In the dynamic field of healthcare, understanding the intricate relationships between symptoms and diseases is crucial for precise diagnosis and predictive analytics. This study delves into these complex interactions using network analysis, blending theoretical frameworks with empirical data. Our objectives are twofold: to unravel the complexi- |                                    |           |
| d               | Most Important Actors . . . . .        | 7        |  |                                    |           |
| <b>6</b>        | <b>ML Model Methodology</b>            | <b>9</b> |  |                                    |           |
| a               | Preliminary Data Preparation . . . . . | 9        |  |                                    |           |
| b               | Feature Extraction . . . . .           | 10       |  |                                    |           |
| c               | Model Choice . . . . .                 | 10       |  |                                    |           |

ties of these relationships and to identify key features that enhance predictive modeling.

Central to our analysis are complex network configurations, where we employ bipartite models and non-weighted edges to discover significant patterns. We use a range of network metrics, comparing our results with null models to ensure statistical reliability. Our application of community detection algorithms reveals hidden structures and relationships among diseases, enriching our understanding.

We introduce innovative metrics based on the work of Hidalgo and Hausmann [5] and Hidalgo et al. [4], which help classify symptoms and diseases according to their predictive strength. These metrics, along with traditional ones like betweenness centrality, are key in characterizing our predictive models.

Building on this analytical groundwork, we venture into predictive modeling with the goal of exceeding current benchmarks. In line with research by Kohli and Arora [6], Singh and Kumar [8], and Uddin et al. [12], which highlights the efficacy of Logistic Regression, Random Forest, and Multi-Layer Perceptron algorithms in disease prediction from symptomatic data, we focus on these models for our analysis.

## 2. DATASET

The dataset used for this project is obtained from Kaggle and is available at the [following link](#). It comprises disease names along with the symptoms reported by the respective patients.

**Overview:** The dataset encompasses 773 unique diseases and 377 symptoms, resulting in approximately 246,000 rows. It was artificially generated while preserving Symptom Severity and Disease Occurrence Possibility.

**Data Encoding:** To facilitate model training, the dataset utilizes one-hot encoding for each symptom, transforming categorical symptom data into a binary format.

**Class Imbalance:** The original dataset exhibited significant class imbalance, with some classes having only one sample and others containing thousands. We addressed this problem using Oversampling and Undersampling techniques, and the details are further elaborated in Section a.

**Data Cleaning:** To allow consistent Oversampling, classes (diseases) with fewer than three symptoms were excluded from the dataset, resulting in the removal of 25 classes. Additionally, diseases with no symptoms and symptoms with no associated diseases were deleted as well.

## 3. GOALS

The final objective of this project is to develop a robust **machine learning model** capable of predicting diseases based on reported symptoms. In pursuit of this goal, *two specific objectives* are outlined, both centered around **leveraging the network structure**:

1. **Feature Extraction:** Exploiting the network characteristics and metrics, aiming to extract novel features that can enhance the predictive capabilities of

the model.

2. **Complexity Reduction:** Leveraging network information, we aim to reduce the number of symptoms, retaining only the most relevant ones. This strategic reduction aims to decrease training time while preserving the accuracy of the model.

By integrating these two objectives, the project aspires to not only advance the predictive capabilities of the machine learning model but also optimize its efficiency in handling the complexities inherent in disease prediction based on symptoms.

## 4. NETWORK METHODOLOGY

In this section there is a technical description of the methodology used to create and analyze the network.

### a. Network Creation

In this project, a bipartite graph was created where nodes represent symptoms (lightcoral) and diseases (lightblue), and edges denote the presence of symptoms in diseases. For simplicity, the graph is unweighted, and all edges have a weight of 1. Prior to graph creation, a preliminary data analysis was conducted to identify isolated nodes. Additionally, an analysis of the node degree distribution was performed to assess whether the distribution follows a power law (see Section 5.1).

The analysis revealed the presence of several symptoms, precisely 52 out of 377, not associated with any disease. Consequently, these isolated symptoms were removed from the graph as they do not contribute informative content. Diseases without associated symptoms were also removed for the same reason.

Figure 1 illustrates the resulting bipartite graph. As observed, diseases tend to be peripheral, while symptoms tend to be central. This observation arises from the fact that symptoms are shared by multiple diseases, whereas diseases exhibit distinct symptoms. Furthermore, symptoms are fewer in number than diseases, making it more likely for a symptom to be shared among multiple diseases.

Figure 2 presents the unipartite graphs of symptoms and diseases.





Fig. 2: Visual representation of symptom and disease unipartite graphs.



**Fig. 1:** Visual representation of the symptom-disease bipartite graph.

## b. Method of Reflections

To identify influential nodes in the symptom-disease network, we introduce two indices that capture the relative importance of each actor. The first index, referred to as the Symptom Influence ( $SI$ ) index, not only ranks symptom nodes based on their frequency (level-1) but also considers whether a symptom is present in diseases affected by numerous other symptoms (level-2) or in diseases affected by only a few symptoms.

Conversely, the second index, known as the Disease Influence ( $DI$ ) index, assesses the distinct symptoms related to a disease (level-1) and whether a disease exhibits symptoms that affect many other diseases (level-2).

In other words, level-1 of these indices quantifies the number of symptoms associated with a disease, while level-2 measures the interconnectedness and broader impact of symptoms or diseases within the network. For the Symptom Influence ( $SI$ ) index, level-2 takes into account the presence of a symptom across diseases, shedding light on whether a particular symptom tends to co-occur with a wide range of other symptoms or is more specific to a subset of diseases. This dual-level analysis provides a nuanced understanding of the significance of symptoms based not only on their individual prevalence (level-1) but also on their associations with other symptoms across different diseases (level-2). Similarly, for the Disease Influence ( $DI$ ) index, level-2 assesses the extent to which a disease's symptoms have ripple effects on other diseases, indicating the potential for cascading impacts within the network.

We adapt the level- $N$  indices following the approach of Hidalgo et al.,[4] and Hidalgo and Hausmann,[5]. The level- $N$

indices are defined as:

$$SI_{v,N} = \frac{1}{SI_{v,1}} \sum_u W(v,u) DI_{u,N-1} \quad (1)$$

$$DI_{u,N} = \frac{1}{DI_{u,1}} \sum_v W(v,u) SI_{v,N-1} \quad (2)$$

Here,  $SI_{v,1}$  and  $DI_{u,1}$  represent the level-1 indices, and  $W(v,u)$  denotes the edge weight between symptom  $v$  and disease  $u$ . The level-1 indices are defined as follows:

$$SI_{v,1} = \sum_u W(v,u) \quad (3)$$

$$DI_{u,1} = \sum_v W(v,u) \quad (4)$$

Since our network is not weighted ( $W(v,u) = 1$  if symptom  $v$  is associated with disease  $u$  and  $W(v,u) = 0$  otherwise),  $SI_{v,1}$  and  $DI_{u,1}$  are equal to the degree of symptom  $v$  and disease  $u$ , respectively.

### Statistical Validation of $SI$ and $DI$

In our effort to identify significant nodes within the symptom-disease network, we focus on discerning topological properties that hold statistical significance. Our goal is to differentiate higher-order properties that are directly associated with local node features from those that emerge from the intricate interactions among nodes.

Relevant studies Squartini, Fagiolo, and Garlaschelli [11, 10] and Spelta, Pecora, and Pagnottoni [9] highlight how higher-order network properties naturally capture structured group interactions. Here, a ‘group’ is defined as all players connected by a ‘hyperlink’, representing the

higher-order analog of a link.

The sampling of random graphs with specified properties plays a pivotal role in network analysis, serving as fundamental null models for identifying patterns, including communities and motifs.

To statistically assess the significance of SI and DI, we adopt a hypothesis testing approach based on a null model. Specifically, we posit **H0** as the hypothesis that SI and DI level-2 do not offer additional information compared to level-1, and **H1** as the opposite. To test these hypotheses, we generate 5000 random networks using a null model with the same level-1 properties as the original network.

With this ample set of null models, we assume that the distribution of SI and DI is Gaussian, leveraging the Central Limit Theorem (CLT). For each null model, we calculate the mean ( $\mu$ ) and standard deviation ( $\sigma$ ) of SI and DI and compute the z-score for each SI and DI level-2, as expressed in the following equation:

$$z_{SI_{v,2}} = \frac{SI_{v,2} - \mu_{SI_{v,2}}}{\sigma_{SI_{v,2}}} \quad (5)$$

If **H0** holds true, the z-scores of SI and DI should be normally distributed with a mean of 0 and a standard deviation of 1. Conversely, if **H1** is true, the z-scores of SI and DI should be normally distributed with a mean and standard deviation different from 0 and 1, respectively.

### c. Betweenness Centrality

The betweenness centrality of a node  $v$ , as defined by Brandes [2], is calculated as the sum of the fraction of all-pairs shortest paths that pass through  $v$ :

$$c_B(v) = \sum_{s,t \in V} \frac{\sigma(s,t|v)}{\sigma(s,t)} \quad (6)$$

where:

- $V$ : The set of nodes.
- $\sigma(s,t)$ : The number of shortest paths from node  $s$  to node  $t$ .
- $\sigma(s,t|v)$ : The number of those shortest paths from node  $s$  to node  $t$  that pass through some node  $v$  other than  $s$  and  $t$ .
- If  $s = t$ , then  $\sigma(s,t) = 1$ .
- If  $v \in \{s,t\}$ , then  $\sigma(s,t|v) = 0$ .

To compute the betweenness centrality, the NetworkX function `nx.bipartite.betweenness centrality` was utilized. This function implements the algorithm proposed by Brandes [1], specifically designed for bipartite graphs, and includes proper normalization for accurate results.

### d. Communities Detection

Prior to applying any community detection algorithm, two crucial steps must be performed:

- **Graph Projections:** The bipartite graph needs to be projected into two separate graphs, one for each set of nodes. In our case, the two sets represent symptoms and diseases. To achieve this, the NetworkX function `nx.bipartite.projected_graph` is employed, returning the projection of the bipartite graph onto the specified nodes.
- **Compute Similarity:** The similarity between nodes needs to be computed. For our purposes, a co-occurrence matrix is created for each set of nodes. Taking the example of the co-occurrence matrix for symptoms, each entry  $s_{ij}$  represents the number of times the symptom  $i$  and the symptom  $j$  co-occur in the same disease.

Once the two graphs, with links weighted by node similarity, are obtained, the community detection algorithm can be applied. We utilized the Clauset-Newman-Moore greedy modularity maximization algorithm [3], implemented in the NetworkX function `nx.algorithms.community.greedy_modularity_communities`. This algorithm aims to find the partition of the graph that maximizes modularity, defined by Newman [7] as:

$$Q = \frac{1}{2m} \sum_{ij} \left[ A_{ij} - \frac{k_i k_j}{2m} \right] \delta(c_i, c_j) \quad (7)$$

where:

- $Q$ : Modularity of the network.
- $A_{ij}$ : Element of the adjacency matrix representing the connection between nodes  $i$  and  $j$ .
- $k_i$  and  $k_j$ : Degrees of nodes  $i$  and  $j$ , respectively.
- $m$ : Total number of edges in the network.
- $\delta(c_i, c_j)$ : Kronecker delta function, which is 1 if  $c_i$  is equal to  $c_j$  (i.e., nodes  $i$  and  $j$  belong to the same community) and 0 otherwise.
- The sum is taken over all pairs of nodes  $i$  and  $j$ .

## 5. NETWORK RESULTS

### a. Method of reflection

We conducted an in-depth analysis of the Symptom Influence (SI) and Disease Influence (DI) indices, considering both level-1 and level-2 metrics in our symptom-disease network.

#### Level-1 Metrics

For the level-1 metrics, which quantify the individual prevalence of symptoms and diseases, we observed distinctive patterns, as illustrated in Figure 3. The Symptom Influence (SI) at level-1, representing the number of diseases associated with a symptom, demonstrated a wide distribution, ranging predominantly between 0 and 60. This suggests



that certain symptoms exhibit a broad association with various diseases, showcasing the diverse nature of symptom-disease relationships.

Conversely, the Disease Influence ( $DI$ ) at level-1, reflecting the number of symptoms related to a disease, exhibited a narrower range, typically falling between 2 and 12. This narrower range indicates that diseases tend to have a more focused set of associated symptoms.




Fig. 3: Degree Distribution (level 1)

### Level-2 Metrics

Moving to the level-2 metrics, which capture the interconnectedness and broader impact of symptoms or diseases within the network, we uncovered intriguing patterns (see Figure 4). The Symptom Influence ( $SI$ ) at level-2, reflecting the presence of symptoms across diseases and their associations with other symptoms, exhibited values ranging from 4 to 12. This suggests that certain symptoms not only co-occur within diseases but also form meaningful connections with a diverse set of other symptoms. A higher level-2 Symptom Influence ( $SI$ ) implies a symptom's propensity to be associated with a wide range of symptoms, indicating its potential impact on various disease pathways.

On the other hand, the Disease Influence ( $DI$ ) at level-2, quantifying the ripple effects of a disease's symptoms on other diseases, demonstrated a wider range, typically spanning from 10 to 80. This broader range signifies that certain diseases have a more extensive influence on the network by affecting a multitude of other diseases. A higher level-2 Disease Influence ( $DI$ ) implies that a disease's symptoms not only contribute to its immediate associations but also have far-reaching consequences, affecting a network of interconnected diseases.

These results highlight the diverse roles played by symptoms and diseases in influencing the network when considering higher-order interactions.




Fig. 4: L2 Distribution for both symptoms and diseases

### Power Law CCDF

In our statistical validation of the Symptom Influence ( $SI$ ) and Disease Influence ( $DI$ ) indices at both level-1 and level-2, the analysis of the complementary cumulative probability distribution (CCDF) reveals distinctive pat-

terns.

For level-1 diseases, the CCDF power-law behavior exhibits a rapid decrease, indicating that a small number of diseases have a disproportionately high influence. This steep decline suggests the presence of disease hubs that significantly impact the network dynamics. Conversely, for level-1 symptoms, the power-law CCDF demonstrates a slow decrease, starting at 0 and extending until 100. This suggests a more distributed influence of symptoms across diseases, with a considerable number of symptoms exhibiting varying degrees of prevalence. The gradual decline in the CCDF emphasizes the diverse roles played by symptoms in the network.

Level-2 diseases, on the other hand, exhibit a slower power-law decrease, starting at 50 and reaching zero around 90. This gradual decline implies that a broader range of diseases contributes to the interconnectedness within the network, with a subset of diseases exerting influence across multiple others.

Finally, for level-2 symptoms, the power-law CCDF displays a rapid decrease around 10, emphasizing the existence of highly influential symptoms that play a pivotal role in connecting various diseases.




Fig. 5: Power Law Distribution of the level 1 and level 2 metrics

### Statistical Validation of $SI$ and $DI$

In our statistical validation of the Symptom Influence ( $SI$ ) and Disease Influence ( $DI$ ) indices at level-2, we aimed to discern whether these higher-order metrics provide additional information compared to level-1, and whether this information is statistically significant. Our null hypothesis ( $H_0$ ) posited that level-2 metrics do not offer additional insights beyond level-1, while the alternative hypothesis ( $H_1$ ) suggested the opposite.

Upon generating 5000 random networks with the same level-1 properties as the original network, we calculated z-scores for both Symptom Influence ( $SI$ ) and Disease Influence ( $DI$ ) at level-2.

Remarkably, the z-score distribution (Figure 6) for both symptoms and diseases exhibited a shape quite similar to a Gaussian distribution, with means close to zero.

For symptoms, the z-scores ranged between -4 and 3, indi-

cating that the level-2 Symptom Influence ( $SI$ ) values were generally lower than the mean but still within a reasonable range. This suggests that, on average, symptoms tend to exhibit a level-2 influence that aligns closely with the overall network structure.

Similarly, for diseases, the z-scores ranged from -3 to 4, signifying that the level-2 Disease Influence ( $DI$ ) values were distributed around the mean. This implies that diseases, on average, have a level-2 influence that aligns with the overall network structure, showcasing a balance between localized effects and broader impacts.

The proximity of the mean to zero in both distributions suggests that, on average, the level-2 metrics for both symptoms and diseases do not significantly deviate from the null model. However, the broader range of z-scores signifies the presence of nodes with both positive and negative deviations, underscoring the heterogeneous nature of influences within the symptom-disease network.

In conclusion, our statistical validation reinforces that while the level-2 metrics follow a distribution akin to a Gaussian, the nuanced deviations reflected by the z-scores for both symptoms and diseases underscore the diverse and context-dependent nature of their influences within the intricate network structure.




Fig. 6: Probability Density Function of the z-scores

## b. Betweenness Centrality

The examination of betweenness centrality in our bipartite network, as depicted in Figure 7, reveals a Power Law Distribution, indicative of a scale-free structure. This implies the presence of a few central nodes that act as pivotal connectors, while the majority of nodes exhibit lower betweenness centrality.




Fig. 7: Betweenness Centrality CDFs

Upon dissecting the centrality values into symptoms and diseases (see Figures 8 and 9), a notable observation emerges: symptoms tend to have higher betweenness centrality compared to diseases. To decipher the significance of this result, it's essential to delve into the interpretation of betweenness centrality.




Fig. 8: Betweenness Centrality of the diseases




Fig. 9: Betweenness Centrality of the symptoms

In general, a symptom exhibits high betweenness centrality when it is linked to numerous diseases, and these diseases, in turn, are connected to a relatively limited set of symptoms. Conversely, a disease attains high betweenness centrality when it connects to numerous symptoms, and these symptoms are associated with relatively few diseases.

Analyzing our results (L1 and L2), it becomes evident that the higher betweenness centrality of symptoms is attributed to their connections with a multitude of diseases, while diseases, on the contrary, are linked to a relatively limited number of symptoms. From a predictive standpoint, this outcome presents a challenge as each symptom is not sufficiently specific, contributing to a broad array of disease classes.

Figure 10 highlights the top 10 nodes with the highest betweenness centrality, all of which are symptoms. As anticipated, these symptoms are more generic in nature, aligning with their central role in connecting various diseases.




Fig. 10: Top 10 nodes with the highest betweenness centrality

### c. Communities

The identification of communities within the network serves a dual purpose – facilitating network interpretation and enhancing the capabilities of our ML prediction model. From a network interpretation perspective, communities offer insights into disease-symptom relationships. A community of symptoms signifies a set of symptoms that frequently co-occur within the same diseases, while a community of diseases identifies a set of diseases often co-occurring within the same symptoms. The sizes of different communities are illustrated in Figure 11.




Fig. 11: Sizes of the communities of symptoms and diseases

For clinical relevance, examining symptoms communities provides valuable information about diseases associated with these symptoms. This is exemplified in Figures 12, 37, and 38. As an example, in the symptoms' community 1 (Figure 12), 'burn' has 12 symptoms, which makes it a specific disease for community 1, considering that on average each disease has only three symptoms from that community.




Fig. 12: Community 1 of symptoms

A similar study can be conducted for communities of diseases, as depicted in Figures 13, 39, 40. This information aids in profiling diseases and understanding the significance of each symptom. For instance, in community 1 of diseases (Figure 13), the symptom 'sharp abdominal pain' is present in almost half of the diseases in the community, indicating its generic nature and limited discriminatory value.




Fig. 13: Community 1 of diseases

Transitioning to the creation of features for the ML model, two types of features were developed:

- **Community Count:** This feature counts how many symptoms of the symptom vector belong to each community. Each symptom community is characterized by different pointed diseases. The model can learn to prioritize diseases associated with the community with the highest count.
- **Community Size:** This feature replaces each symptom in the symptom vector with the size of the community to which the symptom belongs. It enables the model to distinguish between symptoms belonging to small and large communities. If many symptoms from small community are present, the associated diseases may be more likely.

It is noteworthy that communities can also contribute to improving the computational efficiency of the model. For example, a symptom associated with many diseases may be less informative and could potentially be removed from the symptom vector. However, we opted for a comprehensive approach using a combination of L1 and L2 measures to address this issue.

### d. Most Important Actors

As previously mentioned, our objective extends beyond feature extraction; we aim to leverage network information

to enhance the computational efficiency of the model. The strategy involves reducing the number of symptoms, retaining only the most significant ones, to decrease training time while maintaining high accuracy. Various approaches were tested, including L1, L2, betweenness centrality, and the degree of the unipartite projection of symptoms. To select the most appropriate approach, we examined the correlation between these features (Figure 14). Indeed, a high correlation between features means that they provide similar information, and therefore retaining both features would be redundant. On the other hand, a low correlation between features indicates that they provide complementary information, and this enhances in a considerable way the quality of the choice.

For this reason, as clearly shown in Figure 14, we decided to use L1 and L2 to discriminate among the symptoms in a more effective manner.

To practically create the classes, we need to define thresholds for L1 and L2. We decided to consider a symptom as important for the prediction of specific diseases if it is present in less than 0.5 times the average of L1 diseases, translating into a threshold of 8.21 for L1. Consequently, we adjusted the L2 threshold to maintain a proper balance between the classes, setting it to 8.




Fig. 15: Symptoms divided into the four classes




Fig. 16: Division based on L1 and L2 values

As demonstrated in Figure 15, the four classes have different sizes, and more importantly, they provide very different

and valuable information.

To shed light on these classes, a brief reminder of the meanings of L1 and L2 is warranted. L1 denotes the number of diseases associated with a symptom, whereas L2 quantifies the number of symptoms linked to those diseases. As a result, we categorize the features into the following classes:

- **Low L1 - Low L2:** Symptoms with low degree and low L2. These symptoms are connected to few diseases which are also connected to few other symptoms. Therefore, we can expect this symptoms to provide a high contribution to the prediction of few specific diseases.
- **Low L1 - High L2:** Symptoms with low degree and high L2. For these symptoms, the same reasoning as above applies, but with lesser strength. Indeed, these symptoms are connected to few diseases, but those diseases are connected to many other symptoms.
- **High L1 - Low L2:** Symptoms with high degree and low L2. These symptoms may be important for the overall performance of the model. For instance, a symptom may be associated with many diseases, but those diseases may only be associated with that symptom. In this case, the symptom is very important for prediction. Since these symptoms are connected to many diseases, they can be considered important for the overall performance of the model, even if they are not crucial for the prediction of specific diseases.
- **High L1 - High L2:** Symptoms with high degree and high L2. As for the previous class, these symptoms are not very specific of a diseases, but we can expect them to be important for the overall accuracy of the model, since they provide information about many diseases.

To check the soundness of our expectations, together with the effect of this approach on the model's computational efficiency, we applied it to the best model and the results are analyzed in Section 7.

Figures 15 and 16 illustrate the division of symptoms into the four classes. The same entire analysis was conducted for diseases, in this case focusing on the high-L1-high-L2 class, which contains the most complex diseases under a symptomatology perspective. The results are reported in Figures 41 and 42.

To provide a complete picture of the most specific symptoms we report the composition of the low-L1-low-L2 class in Figure 17. As we can see there are many symptoms which occur in just one disease. Their presence should make their associated diseases the most probable one. As an example, 'vulvar sore' is only present in the diseases 'poisoning due to antihypertensives'.






Fig. 14: Correlation between features

## 6. ML MODEL METHODOLOGY

This section provides a comprehensive overview of the methodologies employed in the construction of the machine learning model. The discussion encompasses various techniques designed to handle the intricacies of model building, coupled with a logical flow that guides the entire process.

### a. Preliminary Data Preparation

Before delving into model development, a data preprocessing pipeline was employed to properly prepare them for the subsequent steps, facing the problems of class imbalance and training computational complexity.

- **Random Sampling:** Given the extensive nature of hy-

perparameter tuning, we adopted a random sampling strategy, picking around 10% of the dataset. Instead of training the models on the entire dataset for each hyperparameter combination, the random subset was used to expedite the tuning phase without sacrificing model representativity.

- **Class Imbalance with Oversampling and Under-sampling:** The dataset was highly unbalanced across its 700 disease classes. To mitigate this, a combination of oversampling and undersampling techniques was applied. The former was performed for minority classes, while the latter was applied to the majority classes, ensuring all the diseases were adequately represented during training, preventing dominance and biases in the model.




Fig. 17: Composition of the low-L1-low-L2 class for symptoms

## b. Feature Extraction

A pivotal phase in constructing a machine learning model is feature extraction. In addition to the one-hot vector representation of symptoms, the network analysis affords us the following features:

- **L1 and L2 Measures:** A vector with values representing the L1 and L2 measures for each symptom.
- **Betweenness Centrality:** A vector with values denoting the betweenness centrality of each symptom.
- **Community Count:** A vector indicating the number of symptoms belonging to each community.
- **Community Size:** A vector replacing symptoms with the size of the community to which they belong.

Given the diverse scales of these features, normalization becomes imperative for their cohesive integration into the model without introducing biases. To achieve this, we opted for *MaxAbs* normalization. This normalization scales each feature individually, ensuring that the maximal absolute value of each feature in the training set becomes 1.0, while preserving the sparsity of data.

## c. Model Choice

In the expansive landscape of machine learning, numerous classification models are available for disease prediction. Our selection narrows down to three models renowned for their robust predictive capabilities, as substantiated by the findings of Kohli and Arora [6], Singh and Kumar [8], and Uddin et al. [12]. These models are Logistic Regression, Random Forest, and Multilayer Perceptron (MLP).

### Logistic Regression

- **Strengths:** Logistic Regression's computational efficiency makes it an attractive choice for initial exploration and baseline performance assessment. Its simplicity facilitates interpretability, providing insights into the impact of individual symptoms on disease prediction.
- **Considerations:** While efficient, Logistic Regression assumes a linear relationship between features and the log-odds of the target, potentially limiting its ability to capture complex non-linear patterns.

### Random Forest

- **Strengths:** Random Forest is renowned for its robustness in handling large and diverse datasets, making it well-suited for our expansive dataset with 700 disease classes. Moreover, Its ability to capture non-linear relationships ensures that complex patterns within the symptoms' one-hot encoded features are effectively modeled.
- **Considerations:** The ensemble nature of Random Forest provides resilience against overfitting, a crucial factor in the context of disease prediction.

### Multilayer Perceptron (MLP)

- **Strengths:** MLPs are adept at capturing intricate relationships in high-dimensional datasets, aligning with the complexity inherent in our 300-feature symptom representation.
- **Considerations:** Their capacity for adapting to non-linear mappings positions MLPs as powerful tools in unraveling the nuanced interactions between symptoms and diseases.

## d. Operative Flow

Once the features are ready, the core part of the model-building process can begin. The operational flow was quite



Fig. 18: Operative Flow of the ML Model

complex, and it is summarized in Figure 18.

We trained three different models: a Logistic Regression, a Random Forest, and a Multi-Layer Perceptron (MLP). For each model, we faced the challenge of selecting both the best hyperparameters and the most effective features. The interdependence between these two aspects makes the optimal approach to explore all the possible combination of features and for each combination trying all the hyperparameters combination. This approach is not feasible in terms of computational effort leading us to adopt a greedy approach. We firstly split the features into two groups: the symptoms' one-hot vector and the remaining features. The former is used to train a base model, while the latter is utilized to explore the potential improvement brought by the new features.

Using Algorithm 1, we determined the best feature combination for each group (symptoms and other features). Subsequently, given the optimal feature combination, we identified the best Hyperparameters combination using Algorithm 2. Each model was then trained with the best hyperparameters and the best features combination. For each group of three models available at this point (3 models with symptoms and 3 models with other features), we selected the best one according to their accuracy value (Section a). Only at this point the two winning models were trained with the whole dataset to provide a more precise evaluation of their performance and were compared to assess the result of our first Goal.

As regard the last Goal, the best between the above two models undergone the feature reduction process discussed in Section d and its computational time was compared to the one of the full features model.

#### Algorithm 1 Feature Selection Algorithm

```

1: RemainingFeatures  $\leftarrow$  AllFeatures
2: FeatureSet  $\leftarrow$  EmptySet
3: BestAccuracies  $\leftarrow$  EmptySet
4: Parameters  $\leftarrow$  InitializeRandomParameters
5:  $i \leftarrow 0$ 
6: while RemainingFeatures is not Empty do
7:   BestAccuracy  $\leftarrow 0$ 
8:   for each feature in RemainingFeatures do
9:     CurrentFeatureSet  $\leftarrow$  feature  $\cup$  FeatureSet
10:    Model  $\leftarrow$  EmptyModel
11:    TrainModel(model, CurrentFeatureSet, Parameters)
12:    CurrentAccuracy  $\leftarrow$  GetAccuracy(Model)
13:    if CurrentAccuracy  $\geq$  BestAccuracy then
14:      BestAccuracy  $\leftarrow$  CurrentAccuracy
15:      BestFeature  $\leftarrow$  feature
16:   BestAccuracies[i]  $\leftarrow$  BestAccuracy
17:   RemainingFeatures  $\leftarrow$  RemainingFeatures - BestFeature
18:   FeatureSet  $\leftarrow$  BestFeature  $\cup$  FeatureSet
19:   BestFeatureCombinations[i]  $\leftarrow$  FeatureSet
20:    $i \leftarrow i + 1$ 
21: BFC  $\leftarrow$  BestFeatureCombinations[ArgMax(BestAccuracies)]
22: return BFC

```

The quest for optimal hyperparameters (hparams) in machine learning models is often constrained by computational resources. In light of these limitations, we adopted a resource-efficient greedy search strategy to navigate the vast hyperparameter space. Our approach unfolds in several stages. Initially, we randomly initialize hyperparameters (hparams) to initiate the search. Subsequently, we employ a stepwise exploration, beginning with the first hyperparameter. For this, we perform an initial search over a small set of values (e.g., 0.001, 0.01, 1, 10, 100). If the optimum lies at one of the extremes, we extend the search to encompass values in the corresponding direction.; conversely, if it resides within an intermediate range, we conduct a more focused exploration in a narrower interval. This process is iteratively repeated for each hyperparameter, gradually refining our understanding of the optimal regions within the hyperparameter space. This iterative approach serves a dual purpose. First, it conserves computational resources by avoiding an exhaustive search over all potential combinations. Second, it capitalizes on the information gleaned from earlier iterations to guide subsequent searches efficiently. By strategically determining the next set of values based on the observed trends, we strike a balance between exploration and exploitation, ultimately converging to a set of hyperparameters (hparams) that maximizes model performance. This resource-conscious strategy is paramount when computational resources are limited, allowing us to derive meaningful results within practical constraints.

At the conclusion of these procedures, we obtained the following two models:

- **Symptoms Model:** The best model with the optimal hparams and the symptoms as features

**Algorithm 2** Greedy Hyperparameter Search

---

```

1: hparams  $\leftarrow$  randomInitialization
2: for each hparam in hparams do
3:   src_range  $\leftarrow$  initialSrcRange
4:   best_value  $\leftarrow$  curr_hparams[hparam]
5:   accuracy  $\leftarrow$  0
6:   for value in src_range do
7:     curr_hparams[hparam]  $\leftarrow$  value
8:     performance  $\leftarrow$  eval(model, curr_hparams)
9:     if performance better than accuracy then
10:      best_value  $\leftarrow$  value
11:      accuracy  $\leftarrow$  performance
12:   if best_value is at the lower extreme then
13:     src_range  $\leftarrow$  extendSrcRangeLower(best_value)
14:   else if best_value is at the upper extreme then
15:     src_range  $\leftarrow$  extendSrcRangeUpper(best_value)
16:   else
17:     src_range  $\leftarrow$  narrowSrcRange(best_value)
18:   for value in src_range do
19:     curr_hparams[hparam]  $\leftarrow$  value
20:     performance  $\leftarrow$  eval(model, curr_hparams)
21:     if performance better than accuracy then
22:       best_value  $\leftarrow$  value
23:       accuracy  $\leftarrow$  performance
24:   curr_hparams[hparam]  $\leftarrow$  best_value

```

---

- **Other Features Model:** The best model with the optimal hyperparameters and the best features combination

## 7. ML MODEL RESULTS

In this section we present the results of the ML models we have trained. We then deeply inspect the best performing model, in order to understand its features and its performance.


### a. Model Selection

As previously shown by the operative flow in Figure 18, there are several phases involved in the selection of the optimal prediction model. Given our limited resources we chose to take a greedy approach by performing the feature selection first, and then optimizing the hyperparameters at a later time for each of the three models considered.

#### Features Selection


To reduce the amount of time spent training the models to select the best hyperparameters, it is best to first limit the number of features considered. The selection of the most useful features was performed using a forward stepwise selection, following a greedy approach that aims at maximizing the accuracy. The hyperparameters were initialized with the default values provided by the library scikit-learn.

As depicted in Figure 19, we can see that the best accuracy with the logistic regression model is reached after the third iteration, with little improvement with respect to the model using a single feature. This kind of model seems to favor information about communities and the L2 measure. The feature about the community count is weak on its own, being the only one that adds 3 columns, but it seems to carry complementary information with respect to the other features, raising the accuracy by a small margin.



**Fig. 19:** Accuracy of the logistic regression models over the iterations of the forward stepwise feature selection

Figure 20 shows that the random forest models work best with less information than logistic regression. In this case the only features retained are the ones about communities: these results start to reveal which features are the most useful when it comes to classification. It is also worth noting that the best random forest model has a slightly worse accuracy than logistic regression, but that might be due to the random choice of the model's parameters.



**Fig. 20:** Accuracy of the random forest models over the iterations of the stepwise feature selection

The multi-layer perceptron model stands in the middle with respect to the other two models in terms of accuracy. As underlined by Figure 21, unlike the other two cases the model performs its prediction by leveraging only the L2 features, enhanced by the smaller community count. Two steps are enough to reach the best possible test accuracy. This particular implementation of neural network has one hidden layer with 100 neurons, and in our case its performance is better than the random forest model, but still slightly worse than the logistic regression. We expect this to change after the optimization of the hyperparameters, due to the ability

of the MLP to ‘see’ non-linearities.

| Features to be added<br>(Starting from an empty model) | Betweenness | Community count | Community size | Symptoms L1 | Symptoms L2 |
|--|-------------|-----------------|----------------|-------------|-------------|
| 1st iteration  | 87.68%      | 3.84%           | 87.83%         | 87.83%      | 87.83%      |
| 2nd iteration  | 87.61%      | 88.14%          | 87.66%         | 87.66%      |             |
| 3rd iteration  | 87.28%      |                 | 87.49%         | 87.49%      |             |
| 4th iteration  |             |                 | 87.05%         |             | 86.99%      |
| 5th iteration  |             |                 | 86.71%         |             |             |

Fig. 21: Accuracy of the MLP models over the iterations of the stepwise feature selection

## Hyperparameters Selection

### Model Comparison

As illustrated in Figure 18, our model ensemble now comprises six variants: three leveraging only symptoms and three incorporating new network-based features. The selection of the best-performing model from each group was based on test accuracy assessment, where the test is the same balanced dataset in all cases. Figure 22 illustrates consistently low overfitting across all models, showcasing the stability of the symptom-only models. In contrast, Figure 23, portraying the accuracy of models with the new features, reveals some overfitting, particularly in the MLP and Random Forest.

The observed tendency for models with new features to exhibit more pronounced overfitting is unsurprising, given the greater number and complexity of these features compared to symptoms. Notably, despite their different complexity, all models demonstrate similar test accuracy levels, suggesting that a linear separation boundary suffices for effective feature classification. Considering this, we retain the Logistic Regression model as the best-performing model in each group, striking a balance between performance and complexity.




Fig. 22: Accuracy of the three models with only symptoms




Fig. 23: Accuracy of the three models with new features

### b. New Features Effect

The best model from each group was further trained on the full balanced dataset to ensure a more reliable performance evaluation and the test accuracy was computed on the real unbalanced data. The results in Figure 24 reveal a minimal difference between the two groups. This addresses our **first goal**: the new features, only slightly improve the model, offering a comparable performance to using symptoms alone. However, It's essential to note that the new features are more numerous than the symptoms, contributing to a more complex model. In conclusion, the extracted network features are not a superior alternative to symptoms. It is worth to underline that the ‘simplicity’ of the dataset, which leads to a very high accuracy in all models, may also affect the performance evaluation of the new features, which have a small room to improve the model. Therefore, a possible avenue for future exploration could involve the use of more complex dataset, to better assess the performance of the new features.

Another viable option for future work is to use the new features as a complement to the symptoms.




Fig. 24: Accuracy of the best models from both groups

### c. Best Model Analysis

Given that the logistic regression using only symptoms and the one with the new features achieve the same accuracy, we have selected the logistic regression with the new features as the superior model for further analysis. Considering its greater complexity and the absence of overfitting, this model has the potential to capture more nuanced information and intricate patterns.



The model contains 3 group of features: community size, SI index level 2 and community count.

### Performance analysis

The performance of our predictive model, as demonstrated by the confusion matrix in Figure 25, is indicative of its capability to effectively distinguish between different disease classes. These classes are stratified based on their respective Disease Influence (DI) indices.

- **Class 1: Low DI L1 - Low DI L2:** Diseases with a low degree (DI L1) and limited connections to other symptoms (DI L2) tend to be highly specific, which is reflected in the model's precision for such cases. The confusion matrix exhibits a low misclassification rate for these diseases, suggesting that when such specific symptoms are presented, the model can predict with high confidence, albeit for a restricted number of cases.
- **Class 2: Low DI L1 - High DI L2:** Diseases characterized by a low DI L1 but a high DI L2 are connected to a few symptoms, which in turn are associated with a wider array of other diseases. The model's performance for these diseases, as shown in the confusion matrix, presents a moderate degree of accuracy. Misclassifications may occur due to the broader symptom overlap with other diseases.
- **Class 3: High DI L1 - Low DI L2:** A high DI L1 coupled with a low DI L2 signifies diseases with numerous related symptoms, which however, do not significantly influence other diseases. The confusion matrix suggests that such diseases are predicted with a considerable degree of accuracy. The symptoms, while not disease-specific, contribute to a heightened overall model performance due to their prevalence.
- **Class 4: High DI L1 - High DI L2:** Diseases with both high DI L1 and DI L2 indices are those that exhibit common symptoms influencing a multitude of other diseases. The confusion matrix shows that the model is generally accurate in predicting these diseases. However, due to the commonality of symptoms, there is an inherent challenge in precisely classifying them, which could result in a higher misclassification rate with diseases sharing similar symptom profiles.

The aforementioned analysis underscores the complexity inherent in disease-symptom relationships and their impact on predictive modeling. As the confusion matrix corroborates, our model adeptly handles diseases with distinct symptom profiles (Low DI L1 - Low DI L2) but is challenged by diseases sharing common symptoms (High DI L1 - High DI L2). Consequently, the model's performance is a direct reflection of the nuanced interplay between disease prevalence and symptom specificity, as encapsulated by the DI indices.




Fig. 25: Confusion matrix of the predictive model

Figure 26 displays a detailed comparison of the model's diagnostic efficacy for a wide range of diseases, identified by their numerical codes on the x-axis. The graph features two key metrics: the F1 score and accuracy, represented by blue and orange lines, respectively. The accuracy line, mostly stable and high, shows the model's consistent ability to correctly detect both presence and absence of each disease. In contrast, the F1 score line, more varied, reflects the complexity and variability in predicting disease symptoms, illustrating the model's precision and recall for each disease. High points on the F1 score indicate optimal model performance, with a balanced precision and recall, effectively identifying true disease cases without errors. Low points, however, highlight areas where the model is less effective.

### Best and worst performing diseases

Our diagnostic model's effectiveness is analyzed by assessing its performance across different diseases.

Table 1 lists the top ten diseases where the model demonstrates high accuracy. This exceptional performance is further highlighted by near-perfect f1-scores, indicating an optimal balance of precision and recall. Diseases like mitral valve disease, syndrome of inappropriate secretion, and acute bronchospasm stand out with f1-scores of 1.0, exemplifying the model's precision in diagnosing these conditions without any errors.

On the other hand, Table 2 outlines the ten diseases with the lowest accuracy, indicating areas where the model's diagnostic efficiency is limited. While accuracy is lower for these diseases, the f1-scores for conditions like premature ventricular contractions and histoplasmosis reveal that the model, when accurate, maintains reasonable precision and recall. Nevertheless, the notable decline in f1-score for ailments such as vitamin b12 deficiency and otitis media reveals a significant imbalance in the model's diagnostic precision and recall, underscoring the need for targeted improvements in these specific areas.




Fig. 26: A comparison of the F1 score and accuracy for each disease predicted by the model.

| Disease                             | Accuracy | f1-score |
|-------------------------------------|----------|----------|
| mitral valve disease                | 1.0      | 1.000000 |
| syndrome of inappropriate secretion | 1.0      | 1.000000 |
| acute bronchospasm                  | 1.0      | 1.000000 |
| eye alignment disorder              | 1.0      | 1.000000 |
| reactive arthritis                  | 1.0      | 1.000000 |
| joint effusion                      | 1.0      | 0.985507 |
| anal fistula                        | 1.0      | 0.823529 |
| open wound of the shoulder          | 1.0      | 0.791667 |
| alzheimer disease                   | 1.0      | 0.769231 |
| infectious gastroenteritis          | 1.0      | 0.666667 |

Table 1: Accuracy and f1 score for the 10 diseases with the highest accuracy

| Disease                              | Accuracy | f1-score |
|--------------------------------------|----------|----------|
| premature ventricular contractions   | 0.500000 | 0.666667 |
| histoplasmosis                       | 0.498876 | 0.560252 |
| hemiplegia                           | 0.483908 | 0.496462 |
| acute bronchiolitis                  | 0.473684 | 0.562500 |
| poisoning due to antimicrobial drugs | 0.467849 | 0.567968 |
| open wound of the mouth              | 0.394890 | 0.564315 |
| acute otitis media                   | 0.383938 | 0.468456 |
| vitamin b12 deficiency               | 0.333333 | 0.071429 |
| bladder cancer                       | 0.288740 | 0.378102 |
| otitis media                         | 0.250000 | 0.181818 |

Table 2: Accuracy and f1 score for the 10 diseases with the lowest accuracy

### Analysis of bladder cancer

Bladder cancer, as identified in Table 2, is a disease with notably low diagnostic accuracy in our model, prompting a more detailed investigation. Figure 27 illustrates the proportion of bladder cancer cases incorrectly identified by the model, revealing frequent misclassifications, especially as diabetes insipidus and hemiplegia.

Figures 28 and 29 delve deeper, showing the number of bladder cancer cases exhibiting symptoms akin to diabetes insipidus and hemiplegia, respectively. It's striking that 90% of bladder cancer samples share symptoms with diabetes insipidus and hemiplegia, clarifying why the model often confuses bladder cancer with these diseases.

Moreover, an important factor contributing to this diagnostic challenge is the representation of bladder cancer in our dataset. Constituting only 0.36% of the total data, this limited presence may significantly impact the model's ability to accurately identify bladder cancer, leading to its lower accuracy for this specific condition.




Fig. 28: number of samples of bladder cancer and diabetes insipidus that have the same symptoms




Fig. 29: number of samples of bladder cancer and hemiplegia that have the same symptoms

### Analysis of otitis

In a similar vein, we analyzed otitis, another condition exhibiting low diagnostic accuracy. Figure 30 highlights that otitis is frequently misidentified as itching of unknown origin, with a significant 70% of cases being incorrectly classified.

Figure 31 further elucidates this issue, showing that all otitis samples (100%) manifest symptoms similar to those of itching of unknown cause. This overlap in symptoms is a key reason why the model often mistakes otitis for this condition.

The challenge in accurately diagnosing otitis is compounded by its minimal representation in the dataset, amounting to only 0.0016%. Conversely, itching of unknown cause constitutes a slightly larger portion of the dataset (0.018%). This disparity in representation may bias




Fig. 27: Percentage of bladder cancer samples misclassified

the model towards more frequently diagnosing itching of unknown cause, leading to the observed high rate (70%) of misclassification of otitis cases.




Fig. 30: Percentage of otitis samples misclassified




Fig. 31: number of samples of otitis and itching of unknown cause that have the same symptoms

## Most impactful symptoms

Another crucial aspect is to analyze which symptoms are most important for the model. Since the multiclass version of logistic regression assigns a weight to each symptom for every class, we have calculated the average absolute value of these weights for each symptom.

Figure 32 shows the 30 most significant symptoms according to the model. As can be observed, certain symptoms are more influential. These include both ‘community size’ and ‘SI index level 2’ formats, such as ‘sharp chest pain’ and ‘sharp abdominal pain’, among others.

Furthermore, it is noteworthy that among the three network information types obtained, none stands out as more important than the others. All three hold significance, as both ‘community size’ and ‘SI index level 2’ are equally represented among the most important symptoms, and ‘community count’ is significant for the first two out of three communities.

## d. Computational Complexity

After confirming the presence of some symptoms that are more impactful than others, we applied a reduction technique based on their importance, leveraging the division into four classes based on the L1 and L2 Symptom Influence indexes (SI). The first test was to divide the data into four balanced classes, containing 25% of the features each. As shown by Figure 33, the most impactful set of features was the one corresponding to the class with both high SI L1 and L2. This feature class was the one performing better, with only a few classes that were consistently mispredicted. The worst one was the low-low class, which had a class-wise accuracy of less than 20% for most of the disease classes.

Even then, the high-high class by itself would not be a sufficiently good set of features to make predictions, so it was used as a baseline to expand the feature set, retaining increasingly more features. As it can be seen from Figure 34, the model performance is quite good even when using only




Fig. 32: 10 most impactful features




Fig. 33: Histogram of the class accuracy for each feature group, based on SI L1 and L2.




Fig. 34: Comparison between the reduction in features against the reduction on the test accuracy.

a limited amount of features, reaching around 80% test accuracy when using half of the features, which corresponds to a reduction of 10% of the accuracy of the complete model, giving up half the data. This is a good trade-off, but the accuracy is valuable, so we decided to give up at most 1% accuracy, which in this case corresponds to a reduction of the features by almost 30%.

To assess how the reduction of the complexity of the model impacts the training, we repeated the training phase on the whole balanced dataset, recording the difference in time between the two models. In the end, the experimental results showed a reduction in training time of 9.39% caused by a reduction of the training features of 27.87%. The relative time reduction is lower in comparison to the whole model, but it shows promising results that could possibly be even more impactful when dealing with more complex models.



Fig. 35: Visual rendition of the training time reduction compared to the features.

Given the reduction of the features of almost 30%, the accuracy went down by around a percent and a half, but to really assess the quality of the reduced model, we cannot rely only on the test accuracy. Other metrics were employed for the evaluation, which were the precision, recall, and AUC of the ROC. As depicted by Figure 36, the data showed a similar difference in these metrics, with the exception of the AUC being almost identical. This helped us understand that the reduction on the features didn't cause the model to perform well on just the most frequent classes, but resulted in a good performance across the whole data.




Fig. 36: comparison of various metrics which are useful to assess the relative quality of the reduced model.

## 8. CONCLUSION

## 9. LIMITS AND FUTURE WORKS

In the pursuit of our final model, we navigated through a series of pivotal decisions, ranging from model selection, feature choices, and the intricate interplay of normalization techniques to hyperparameter tuning. These decisions, while steering us toward a robust model, come with inherent trade-offs, potentially leading to suboptimal outcomes. Here, we discuss some limitations in our approach and suggest avenues for future exploration.

### a. Limits

- **Feature Selection:** The selection of optimal features, as depicted in Figure 18, occurred before hyperparameter tuning. This sequential approach may result in the choice of an ostensibly optimal feature set, as both aspects are tightly linked.
- **Hyperparameter Tuning:** The determination of the best hyperparameter combination relied on accuracy as the sole metric. While we employed a stratified cross-validation on a balanced dataset for a reliable accuracy estimate, a more comprehensive approach should encompass additional metrics such as precision, recall, and F1-score.
- **Feature Reduction:** The feature reduction process evenly separated the four classes of symptoms and

commenced retaining features from the class demonstrating the highest predictive power. This approach may yield suboptimal results, as a specific threshold might exist beyond which the predictive power of a feature diminishes. To better clarify this concept, let's consider the following example: suppose we have only two classes of symptoms, evenly distributed using the median as a threshold on the degree value. Suppose also that the predictive power of the features is the same for both classes. In this case we cannot actually say that the degree doesn't impact the predictive power of the model. Indeed in the high degree class we can have put lots of features with a degree not sufficiently high to become less relevant and these diseases end up altering the result of the whole class, especially in a power law distribution context. A refined strategy involves employing a manual threshold for the degree value, identifying truly impactful features, potentially resulting in unbalanced classes.

### b. Future Work

- **Symptoms Communities:** The features extracted from symptom communities were integrated into the model based on their inherent ability to capture relevant information. A potential enhancement involves leveraging this knowledge explicitly, using it as prior probability for the model. This entails favoring the most common diseases associated with the patient's symptoms and their communities.
- **Multi-label Classification:** Our current approach treats diseases as independent entities. However, some diseases may be intricately connected. A prospective improvement entails treating diseases as a multi-label classification problem. For instance, the model could output the three most likely diseases instead of a singular one.
- **Disease Complexity Analysis:** Our accuracy analysis extends to different classes of diseases based on their L1 and L2 values. A potential refinement involves a nuanced exploration of disease complexity, adjusting L1 and L2 thresholds to maximize accuracy differentials among disease classes. This approach would facilitate an in-depth analysis of diseases that pose higher prediction challenges.



# 10. APPENDIX




Fig. 37: Community 2 of symptoms




Fig. 38: Community 3 of symptoms




Fig. 39: Community 2 of diseases






Fig. 40: Community 3 of diseases



**Fig. 41:** Diseases divided into the four classes



**Fig. 42:** Composition of the high-L1-high-L2 class for diseases

## REFERENCES

- [1] Ulrik Brandes. “A Faster Algorithm for Betweenness Centrality”. In: *The Journal of Mathematical Sociology* 25 (Mar. 2004). DOI: [10 . 1080 / 0022250X.2001.9990249](https://doi.org/10.1080/0022250X.2001.9990249).
- [2] Ulrik Brandes. “On variants of shortest-path betweenness centrality and their generic computation”. In: *Social Networks* 30.2 (May 2008), pp. 136–145. ISSN: 0378-8733. DOI: [10.1016/j.socnet.2007.11.001](https://doi.org/10.1016/j.socnet.2007.11.001).
- [3] Aaron Clauset, M. E. J. Newman, and Cristopher Moore. “Finding community structure in very large networks”. In: *Physical Review E* 70.6 (Dec. 2004). arXiv:cond-mat/0408187, p. 066111. ISSN: 1539-3755, 1550-2376. DOI: [10 . 1103 / PhysRevE . 70 . 066111](https://doi.org/10.1103/PhysRevE.70.066111).
- [4] C. A. Hidalgo et al. “The Product Space Conditions the Development of Nations”. In: *Science* 317.5837 (July 2007), pp. 482–487. ISSN: 0036-8075. DOI: [10.1126/science.1144581](https://doi.org/10.1126/science.1144581).
- [5] César A. Hidalgo and Ricardo Hausmann. “The building blocks of economic complexity”. In: *Proc. Natl. Acad. Sci. U.S.A.* 106.26 (June 2009), pp. 10570–10575. DOI: [10 . 1073 / pnas . 0900943106](https://doi.org/10.1073/pnas.0900943106).
- [6] Pahulpreet Singh Kohli and Shriya Arora. “Application of Machine Learning in Disease Prediction”. In: *2018 4th International Conference on Computing Communication and Automation (ICCCA)*. IEEE, pp. 14–15. DOI: [10.1109/CCAA.2018.8777449](https://doi.org/10.1109/CCAA.2018.8777449).
- [7] M. E. J. Newman. “Modularity and community structure in networks”. In: *Proceedings of the National Academy of Sciences of the United States of America* 103.23 (June 2006), pp. 8577–8582. ISSN: 0027-8424. DOI: [10.1073/pnas.0601602103](https://doi.org/10.1073/pnas.0601602103).
- [8] Archana Singh and Rakesh Kumar. “Heart Disease Prediction Using Machine Learning Algorithms”. In: *2020 International Conference on Electrical and Electronics Engineering (ICE3)*. IEEE, pp. 14–15. DOI: [10.1109/ICE348803.2020.9122958](https://doi.org/10.1109/ICE348803.2020.9122958).
- [9] Alessandro Spelta, Nicoló Pecora, and Paolo Pagnottoni. “Assessing harmfulness and vulnerability in global bipartite networks of terrorist-target relationships”. In: *Social Networks* 72 (Jan. 2023), pp. 22–34. ISSN: 0378-8733. DOI: [10 . 1016 / j . socnet . 2022.08.003](https://doi.org/10.1016/j.socnet.2022.08.003).
- [10] Tiziano Squartini, Giorgio Fagiolo, and Diego Garlaschelli. “Randomizing world trade. I. A binary network analysis”. In: *Phys. Rev. E* 84.4 (Oct. 2011), p. 046117. ISSN: 2470-0053. DOI: [10 . 1103 / PhysRevE.84.046117](https://doi.org/10.1103/PhysRevE.84.046117).
- [11] Tiziano Squartini, Giorgio Fagiolo, and Diego Garlaschelli. “Randomizing world trade. II. A weighted network analysis”. In: *Phys. Rev. E* 84.4 (Oct. 2011), p. 046118. ISSN: 2470-0053. DOI: [10 . 1103 / PhysRevE.84.046118](https://doi.org/10.1103/PhysRevE.84.046118).
- [12] Shahadat Uddin et al. “Comparing different supervised machine learning algorithms for disease prediction”. In: *BMC Med. Inf. Decis. Making* 19.1 (Dec. 2019), pp. 1–16. ISSN: 1472-6947. DOI: [10 . 1186/s12911-019-1004-8](https://doi.org/10.1186/s12911-019-1004-8).